|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C21H24F3N3S |
|||
| Molecular Weight | 407.50 | CAS No. | 117-89-5 | |
| Solubility (25°C)* | In vitro | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Biological Activity
| Description | Trifluoperazine (NSC-17474, RP-7623, SKF-5019) is an FDA-approved antipsychotic drug for schizophrenia. It is an inhibitor of calmodulin (CaM) and Dopamine D2 receptor with an IC50 value of 1.2 nM for D2 receptor. |
|---|
Protocol (from reference)
Selleck's Trifluoperazine has been cited by 10 publications
| Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions [ Chem Biol Interact, 2024, 395:111023] | PubMed: 38677539 |
| Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronyltransferase (UGT) 1A1 [ Curr Drug Metab, 2024, 25(3):197-204] | PubMed: 38803186 |
| Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions [ Toxicol Appl Pharmacol, 2023, 466:116490] | PubMed: 36963523 |
| RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599] | PubMed: 37797618 |
| In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms [ Toxicol Lett, 2022, 367:3-8] | PubMed: 35810997 |
| Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase [ Toxicol Appl Pharmacol, 2021, 424:115595] | PubMed: 34038714 |
| In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions [ Toxicol Lett, 2021, 348:10-17] | PubMed: 34044055 |
| Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions [ Biomed Chromatogr, 2021, e5205] | PubMed: 34192355 |
| Sphingosylphosphorylcholine alleviates hypoxia-caused apoptosis in cardiac myofibroblasts via CaM/p38/STAT3 pathway [ Apoptosis, 2020, 25(11-12):853-863] | PubMed: 33068199 |
| Inhibition of Human UDP-Glucuronosyltransferase Enzyme by Belinostat: Implications for Drug-Drug Interactions [ Toxicol Lett, 2020, S0378-4274(20)30494-X] | PubMed: 33290829 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.